San Francisco, California-- (Newsfile Corp. - March 17, 2025) - Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the ...

Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...

The Cigna Group Completes Sale of Medicare Businesses to HCSC The transaction is not expected to disrupt coverage or s ...

Scaling Obesity and CV-Met For the new obesity therapeutics making ... Eli Lilly (valued at over $500 billion by end 2023) and Novo Nordisk (valued at over $450 billion), could achieve this ...

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo ...

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

In this video, I will cover the recent updates regarding Novo Nordisk (NYSE: NVO). Watch the short video to learn more, ...

Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now ...

We recently published a list of 10 Stocks Market Experts are Talking About These Days. In this article, we are going to take ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.